Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction the CSL112–2001 trial

ConclusionThese results demonstrate the acceptable safety of the 6 g dose of CSL112 among AMI subjects with moderate stage 3 CKD, and support inclusion of these patients in a phase 3 cardiovascular outcomes trial powered to assess efficacy.
Source: American Heart Journal - Category: Cardiology Source Type: research